Results 11 to 20 of about 69 (69)

New Insights Into Pyridoxal Kinase Inhibitors and Their Antileukemic Effects

Cureus, 2023
Pyridoxal kinase (PDXK) plays a pivotal role as an essential enzyme in cellular processes. It catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine to generate pyridoxal 5'-phosphate (PLP), the bioactive form of vitamin B6. An intriguing link has emerged between elevated expression levels of PDXK and PLP and various types of ...
Banerjee, Pallabi, Singh, Tripti, Qamar, Imteyaz   +2 more
openaire   +2 more sources

Crystal Structures of Human Pyridoxal Kinase in Complex with the Neurotoxins, Ginkgotoxin and Theophylline: Insights into Pyridoxal Kinase Inhibition

PLoS ONE, 2012
Several drugs and natural compounds are known to be highly neurotoxic, triggering epileptic convulsions or seizures, and causing headaches, agitations, as well as other neuronal symptoms. The neurotoxic effects of some of these compounds, including theophylline and ginkgotoxin, have been traced to their inhibitory activity against human pyridoxal ...
K. Gandhi Amit, Jigar V. Desai, Mohini S. Ghatge, DI SALVO, Martino Luigi, Stefano Di Biase, Danso Danquah Richmond, Faik N. Musayev, CONTESTABILE, Roberto, Verne Schirch, K. Safo Martin   +9 more
openaire   +6 more sources

Update: Enzymatische Synthese für industrielle Anwendungen

Angewandte Chemie, EarlyView.
Die Biokatalyse hat sich zu einer nachhaltigen und wettbewerbsfähigen Alternative zur herkömmlichen chemischen Synthese entwickelt und ermöglicht die enzymbasierte Herstellung nicht nur von chemischen Grundstoffen, sondern auch von (nicht natürlichen) Aminosäuren, (seltenen) Zuckern und synthetischen Nukleotiden.
Thomas Bayer, Shuke Wu, Radka Snajdrova, Kai Baldenius, Uwe T. Bornscheuer   +4 more
wiley   +1 more source

An Update: Enzymatic Synthesis for Industrial Applications

Angewandte Chemie International Edition, EarlyView.
Biocatalysis has become a sustainable and cost‐competitive alternative to established chemical synthesis, enabling the enzyme‐based production of not only commodity chemicals but (non‐natural) amino acids, (rare) sugars, as well as synthetic nucleotides.
Thomas Bayer, Shuke Wu, Radka Snajdrova, Kai Baldenius, Uwe T. Bornscheuer   +4 more
wiley   +1 more source

Affinity labeling of pyridoxal kinase with adenosine polyphosphopyridoxal.

Journal of Biological Chemistry, 1988
Pyridoxal kinase is inactivated by preincubation with the affinity label reagent adenosine tetraphosphate pyridoxal (AP4-PL) at a mixing molar ratio of 5:1 AP4-PL contains structural features of the substrates pyridoxal and ATP. The substrate ATP affords substantial protection against inactivation.
DOMINICI, Paola, G. SCHOLZ, F. KWOK, J. E. CHURCHICH   +3 more
openaire   +4 more sources

Mammalian Tolerance to Amino Acid Heterochirality

ChemBioChem, Accepted Article.
Organisms use amino acids predominantly in l‐configuration. On the other hand, a series of studies show that a variety of d‐amino acids also occur in mammals and amino acid homochirality is not complete. Mammals de novo synthesize most amino acids with l‐configuration, but serine and aspartate are converted from l‐ to d‐configuration by endogenous ...
Jumpei Sasabe, Sakiko Taniguchi, Kenichiro Adachi, Xuan Tran, Masataka Suzuki   +4 more
wiley   +1 more source

Crystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives [PDF]

Journal of Biological Chemistry, 2005
Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+. This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of
Lin Tang, Hervé Galons, Tao Jiang, Dong-Cai Liang, Nathanael S. Gray, Feng Wang, Jens Reinhardt, Yongqin Wan, Yoan Ferandin, Minghui Li, Stéphane Bach, Wenrui Chang, Laurent Meijer, Peng Cao   +13 more
openaire   +3 more sources

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

Exploration, EarlyView.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu, Guiyu Dai, Yanyan Chen, Lihua Tan, Hanqing Liu, Meiwan Chen   +5 more
wiley   +1 more source

Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?

Acta Ophthalmologica, EarlyView.
Abstract Gyrate atrophy of the choroid and retina (GACR; OMIM #258870) is a rare early‐onset autosomal recessive disorder, caused by bi‐allelic pathogenic variants in the gene coding for ornithine aminotransferase (OAT) resulting in hyperornithinaemia.
Mark J. N. Buijs, Berith M. Balfoort, Marion M. Brands, Anneloor L. M. A. ten Asbroek, Camiel J. F. Boon, Roselie M. H. Diederen, Corrie Timmer, Margreet A. E. M. Wagenmakers, Hans R. Waterham, Ronald J. A. Wanders, Riekelt H. Houtkooper, Clara D. van Karnebeek, Arthur A. Bergen   +12 more
wiley   +1 more source